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Objective: The optimal prophylactic strategy and treatment regimen for deep venous thrombosis (DVT) in hospitalized
pediatric patients is not clearly established. This study assessed the incidence, risk factors, and treatment patterns for DVT
among pediatric patients admitted to a hospital ward.
Methods: Children (aged <17 years) admitted to a single tertiary-care hospital during a 14-year period who developed or
presented with DVT were retrospectively identified. Patient demographic and clinical data were analyzed retrospectively.
Patients who developed DVT in the hospital were stratified according to the Wells clinical probability scoring system from
criteria noted before the diagnosis. Treatment patterns and outcomes were evaluated between the two time intervals of
1992 to 2001 (group I) and 2002 to 2005 (group II).
Results: Between 1992 and 2005, 358 children were evaluated for DVT, and 99 (52 boys, 47 girls) were admitted to the
hospital and were determined to have DVT by confirmatory imaging. A prior DVT (12 total) was present in eight of the
21 patients admitted for DVT treatment; of the remaining, only seven received DVT prophylaxis on admission. In those
developing a DVT, the inpatient clinical probability score was 21% (low), 40% (moderate), and 39% (high). The most
common risk factor in those with prehospital DVT was a prior DVT (38%) or thrombophilic condition (33%), whereas
inpatients had a central catheter (45%), with nearly 50% in the femoral vein. Children acquiring an inpatient DVT had
concomitant severe respiratory (17%), oncologic (14%), and/or infectious (15%) diseases and required a prolonged
intensive care unit (12.7 days) stay. Prehospital DVT was lower extremity predominant (90%) and statistically different
from inpatient-acquired DVT (62%, P  .01). Treatment patterns between periods I and II revealed a trend to more
low-molecular-weight heparin and less unfractionated heparin use (P  .09). Three patients died (one fatal pulmonary
embolism). The number of recognized cases per 10,000 admissions increased from 0.3 to 28.8 from 1992 to 2005.
Conclusion: The incidence of DVT in hospitalized children is increasing. Those presenting with DVT typically have prior
DVT, thrombophilia, or lower extremity disease. Our study suggests that children admitted with severe medical
conditions who require a prolonged intensive care unit stay in addition to central venous access (especially via the femoral
vein) should be considered candidates for DVT prophylaxis. A clinical probability scoring system alone cannot stratify
patients sufficiently to forgo prophylaxis in hopes of a rapid clinical diagnosis. Childhood-specific level 1 trials aimed at
determining guidelines for DVT prophylaxis are urgently required. ( J Vasc Surg 2008;47:837-43.)Pediatric venous thromboembolic events (VTEs) are
rare, only occurring in 0.07 to 0.14 per 10,000 children
within the general population (5.3 per 10,000 child hospi-
tal admissions, 0.24 per 10,000 neonatal admissions, and
0.51 per 10,000 births).1-5 Despite the relatively low inci-
dence in children, studies suggest that pediatric VTEs are
an increasing concern in tertiary-care hospitals. Epidemio-
logic data indicate that the incidence of VTEs peaks in
newborns/infants and adolescents as a result of diminutive
blood vessels, a unique hemostatic system, and the use of
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doi:10.1016/j.jvs.2007.11.054central venous catheters in the former, and smoking, con-
traception, and obesity in the latter. Other etiologic trig-
gers include exogenous (ie, congenital heart disease, can-
cer, prematurity, trauma, and sepsis) and endogenous (ie,
congenital thrombophilias) factors, which cause physio-
logic alterations in hemostasis or fibrinolysis, or both, and
consequently lead to VTEs.6-8
Because of these specific characteristics, some argue
that pediatric venous thrombosis constitutes a different
pathophysiologic process than that observed in adults. As a
result, many support the concept that children should not
be treated the same as adults.9,10 Medical treatments for
pediatric venous thrombosis have largely been extrapolated
from adult guidelines. Regardless of these treatment guide-
lines, unresolved issues remain because of the lack of defin-
itive studies on the optimal prevention and management of
children with VTEs.11
The apparent increase in childhood VTEs noted in
tertiary-care facilities underscores the need to define those
at risk for deep venous thrombosis (DVT), to define the
need for prophylaxis, and to determine the optimal anti-
thrombotic therapy for this select group of patients with
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factors, and level of prophylaxis in those afflicted and treat-
ment of DVT among hospitalized children within our
tertiary-care referral system. In addition, we sought to
evaluate DVT treatment patterns between two time periods
(1992 to 2001 vs 2002 to 2005) to determine the practical
effect of published guidelines on treatment.
METHODS
Patients. The Indiana University/Purdue University
Institutional Review Board reviewed and approved the
study protocol. We conducted a retrospective observational
cohort study using a computerized medical database cov-
ering a 14-year period from 1992 to 2005. We identified
infants and children aged 0 to 17 years who were evaluated
for DVT and restricted our sample to inpatients presenting
with or developing DVT while hospitalized. We collected
demographic data from these patient charts, including age,
sex, race, year of diagnosis, admitting index diagnosis (cir-
culatory, respiratory, acute infection, malignancy, trauma,
or surgery), admitting service (medicine or surgery), length
of hospitalization (days), intensive care unit (ICU) stay
(days), morbidity, and mortality. Additional risk factors
were obtained from a chart review.
A total of 358 children were evaluated as potentially
having DVT by International Classification of Diseases,
9th Revision, Clinical Modification (ICD-9-CM) codes
(453.40, 453.41, 453.42, 453.80, and 453.90). We ex-
cluded 259 children from the analysis because they had
outpatient records only and either did not have radio-
graphic confirmation or we could not determine the treat-
ment or outcomes from these records. Ninety-nine chil-
dren were admitted to Riley Hospital for Children with a
confirmed DVT. Diagnostic venous imaging included du-
plex ultrasonography (77 %), computed tomography (11
%), venography (8%), magnetic resonance imaging (5%),
and echocardiography (4%). We further stratified these
children into those who presented with a clinical diagnosis
of DVT (prehospital, 21 patients) and those who devel-
oped DVT during their hospitalization (inpatient, 78 chil-
dren).
Risk factor assessment. Several clinical conditions
have been identified as potential risk factors for DVT. We
searched for the following thrombophilic etiologies: central
venous catheter, recent surgery, congenital heart disease,
cancer, immobilization, trauma, nephrotic syndrome, use
of oral contraceptives, congenital thrombophilia (sickle cell
anemia), methylenetetrahydrofolate reductase (MTHFR-
A1298C) mutation, factor V Leiden mutation, prothrom-
bin 20210 (factor II) mutation, decreased antithrombin
III, decreased protein C or protein S, and antiphospholipid
antibodies (cardiolipin and systemic lupus erythemato-
sus).11,12
Patient stratification. If DVT prophylaxis measures
are not routine practice for hospitalized children, we
wanted to know if it was possible to recognize patients with
DVT on clinical grounds, thereby allowing rapid and ap-
propriate diagnostic evaluation and treatment before pa-tient harm. We chose the validated DVT scoring system
described by Wells et al13 to retrospectively categorize
admitted children as having a low, moderate, or high
probability of DVT (Table I) according to criteria observed
before obtaining the confirmatory imaging study. The
DVT risk score ranks specific signs, symptoms, and risk
factors associated with venous thrombosis and assigns a
point score for each. The summation of points along with
the consideration of an alternate diagnosis provides a vali-
dated assessment of DVT risk, at least in adults. The nu-
meric sum obtained categorizes the patient into a low-risk
(0 points), moderate-risk (1 to 2 points), or high-risk
(3) group in terms of the probability of harboring a DVT.
Thromboembolism prophylaxis. Inpatient records
were queried for anticoagulants dispensed or mechanical
forms of prophylaxis used for admitted children without a
prehospital VTE. Pharmacologic and mechanical prophy-
laxis included subcutaneous heparin (heparin sodium and
low-molecular-weight heparin [LMWH]), compression
stockings, and intermittent pneumatic compression. Ap-
propriate prophylaxis was considered if administered in the
recommended dose and duration in the absence of contra-
indications. Patients who were ambulating or discharged
3 days were considered to have undergone appropriate
prophylaxis.
Treatment pattern assessment. We evaluated treat-
ment patterns between two time intervals, the first group
was defined as from 1992 to 2001, and the second group
from 2002 to 2005. The rationale in selecting these time
intervals was such that before 2004, the last American
College of Chest Physician (ACCP) conference on pediat-
ric antithrombotic therapy was updated in 2001.14 We
sought to determine whether significant treatment and
outcome differences existed between the pre-2001 and
post-2001 consensus recommendations.
Statistical analysis. Descriptive statistics were used in
our clinical data to indicate distribution characteristics
among inpatients, treatments, and outcomes. Differences
in treatments and outcomes between groups were assessed
with the 2 test for categoric variables or the Mantel-
Haenszel test for order categories. Values of P  .05 were
Table I. Wells Deep Venous Thrombosis Risk Score13
1 Point Active cancer 6 months or palliation
1 Point Paralysis, paresis, or recent plaster immobilization
1 Point Bedridden 3 days and/or major surgery 12
weeks
1 Point Local tenderness along deep venous system
1 Point Entire leg swollen
1 Point Calf swelling 3 cm symptomless side
1 Point Pitting edema in symptomatic leg only
1 Point Collateral superficial veins
2 Points Alternate diagnosis at least as likely as DVT
Total score
0 Low risk for DVT
1-2 Moderate risk for DVT
3 High risk for DVT
DVT, Deep vein thrombosis.considered significant.
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Our overall incidence of DVT was 9.7 per 10,000
hospital admissions (99 DVTs in 102,502 admissions). Fig
1 shows the annual number of DVTs per 10,000 child
admissions during the 14-year study period. From 1992 to
1995, a prevalence of 0.3 per 10,000 admissions was ob-
served; this trend increased to approximately 9 from 1996
to 2001, to 18 from 2002 to 2004, and precipitously
escalated to 28 per 10,000 admissions in 2005.
Patients presenting with a DVT and those with a DVT
acquired as an inpatient were separate groups of interest.
The children at highest risk for DVT in the prehospital
group were those aged 11 years (85.6%; Fig 2). In
contrast, hospital-acquired DVT was more common in the
children aged 0 to 5 years (38.5%) and 11 to 15 years
(34.6%). Hospitalized children had longer inpatient in-
cumbency, ICU stay, and more deaths by an average of
16.2 days, 12.7 days, and three deaths, respectively (P 
.05; Table II). A higher rate of hematologic admissions was
observed in the prehospital group than in the hospitalized
children (Fig 3). This most likely is attributed to an admit-
ting diagnosis of a DVT. The hospitalized group had a
major diagnoses involving respiratory, infection, or oncol-
ogy, whereas other less common admissions included sur-
gical, trauma, metabolic, or renal (Fig 3). Of note in our
population of children admitted for the evaluation of fever,
23 children were identified who developed DVT; 11 chil-
dren had central venous catheter infections, 4 had a urinary
tract infection, 3 had documented pneumonia, and 1 had
viral gastroenteritis.
A comparison of prehospital and inpatient DVTs by
underlying risk factors present at the time of DVT diagnosis
is summarized in Table III. In the prehospitalized group,
most of the children who presented with DVT had a prior
DVT (38%) or a thrombophilic condition (33%), or both.
Central venous catheters were present in 24% and only in
the upper body. This contrasts with the inpatient group, in
which 45% of the children had DVT at the site of central
venous catheterization, with nearly 50% of these placed in
the femoral location. None of the prehospital DVT patients
Fig 1. Cases of pediatric inpatients with deep venous thrombosis.had a femoral catheter.Only 18% of children with inpatient-acquired DVT had
an identified thrombophilia. Almost all of the prehospital-
ized children (90%) had lower extremity DVT with no
cervical thrombosis noted, whereas hospitalized patients
had 62% lower extremity, 27% upper extremity, and 13%
cervical thromboses (Table IV). Statistically, these rates are
significantly different. This difference in body location is
again reflected in the actual veins affected. The prehospital
children had 80% common femoral and 40% popliteal
thromboses, but no internal jugular vein thromboses. In-
patients developed common femoral (59%) and iliac (18%)
vein involvement but also internal jugular (18%), and sub-
clavian (19%) DVTs. Moreover, a clear association existed
between the presence of a central catheter and the location
of the DVT in terms of vein, body location, and side in the
inpatients. This was obviously not apparent in the patients
who presented to the hospital with a DVT, because no neck
vein thrombosis was noted yet 10% of these patients had a
central catheter in that locale.
Prehospitalized patients were immediately started on
Fig 2. Age distribution of pediatric patients with deep venous
thrombosis.
Table II. Patient demographics in prehospital and
hospitalized children with deep venous thrombosis
Variable Prehospital Inpatient
Age, mean (SD) years 13.8 (3.7) 9.2 (6.4)
Range, y 4 y-17 y 5 w-17 y









LOS, mean (SD) days
Hospital 6.6 (4.8) 22.8 (23.5)a
Intensive care unit 0 12.7 (22.1)a
Deaths, % 0 3a
LOS, Length of stay; SD, standard deviation.
aDenotes P  .05anticoagulation for DVT treatment and therefore were not
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remaining children, only seven patients (9.2%) received
pharmacologic or mechanical prophylaxis, of which three
children were at moderate risk and four were high risk for
DVT by the Wells criteria. We calculated that 21% were
low-risk, 40% were moderate-risk, and 39% were in the
high-risk category for DVT. On the sole basis of these
clinical criteria, the clinician would not suspect the pres-
ence of DVT in at least 21% of these patients. It is
interesting that the diagnosis of DVT in 12 patients was
found serendipitously on a study obtained for an entirely
different clinical indication.
Treatment patterns for DVT during two time intervals,
from 1992 to 2001 (group I) and from 2002 to 2005
(group II), were separated for analysis (Table V). For
short-term treatment, the initial treatment for both groups
was most commonly LMWH, but there was a trend to
provide this therapy more commonly in group II, with a
concomitant decrease in the use of unfractionated heparin.
Fig 3. Principal diagnosis on admission.
Table III. Underlying risk factors among prehospital









Femoral 0 22 .02
Subclavian 14 14 .98
Internal jugular 10 9 .94
Prior DVT 38 5 .01
Congenital thrombophilia 33 18 .13
Malignancy 14 13 .86
Immobility 72 hours 5 4 .85
Trauma 5 6 .78
Oral contraceptive 10 5 .45
Congenital heart disease 5 5 .95
Renal disease 5 4 .85
DVT, deep venous thrombosis.
aDenotes children who presented with a diagnosis of DVT.All other therapies were used sporadically and with similarfrequency during each time period. Discharge treatment
demonstrated a trend in group II to treat all patients
long-term with LMWH, but no difference can be demon-
strated statistically. It is interesting that fewer patients in
group II were treated for at least 3 months, but again, no
statistical difference exists. Only three children with recur-
rent DVT as a result of an inherited thrombophilia were
maintained on lifelong anticoagulation therapy, whereas
those with central catheter–related thrombosis, trauma,
and postoperative-related DVT were treated for shorter
Table IV. Location and anatomic deep venous




(n  21), %
Inpatient
(n  78), % P
Bilateral 10 13 .68
Right 75 50 .03
Left 15 37 .05
Lower extremity 90 62 .01
Upper extremity 10 27 .09
Neck 0 13 .08
Common femoral 80 59 .31
Femoral deep/profunda 5 9 .51
Iliac 10 18 .34
Popliteal 40 8 .01
Internal jugular 0 18 .04
Brachial 5 4 .88
Axillary 5 8 .62
Subclavian 10 19 .62
Infrapopliteal 9 1 .22
Vena cava 0 10 .05
Intracranial sinuses 0 5 .04
Table V. Treatment patterns between groups I (n  42)
and II (n  57)
Treatment pattern Group I, No (%) Group II, No (%) P
Acute treatmenta
LMWH 17 (40.5) 33 (57.9) .09
UFH 17 (40.5) 14 (24.5) .09
ADH 1 (2.4) 0 .24
DTI 4 (9.5) 3 (5.2) .41
IVC filter 2 (4.7) 2 (3.5) .75
CVL removal 4 (9.5) 3 (5.3) .41
None 3 (7.1) 5 (8.7) .77
Discharge treatment
LMWH 16 (38.1) 26 (45.6) .41
Warfarin 13 (30.9) 21 (36.8)
None 11 (26.2) 9 (15.8)
Duration
3 mon 23 (54.8) 44 (77.1) .41
3-6 mon 12 (28.7) 8 (14.0)
6 mon-1 y 6 (14.2) 3 (5.4)
Lifetime 1 (2.3) 2 (3.5)
ADH, Adjusted-dose subcutaneous heparin;CVL, central venous line;DTI,
direct thrombin inhibitor; IVC, inferior vena cava; LMWH, low-molecular
weight heparin; UFH, unfractionated heparin.
aTotal exceeds 100% because some patients received more than one treat-
ment.time periods.
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II (Table VI) showed that most children went home with-
out further incident. Of those with complications, we ob-
served more pulmonary emboli in group II, with one death
as an immediate result of the prothrombotic condition.
Group I had more recurrent DVT and two deaths (1 sepsis
and 1 toxic ingestion). No major bleeding events were
noted in either group. None of these clinical effects were
statistically different when one time period was compared
with the other.
DISCUSSION
Venous thromboembolic events have emerged as an
increased source of concern in hospitalized children. The
absence of large, prospective, randomized clinical trials in
pediatric VTE, attributable in part to its low incidence and
difficulties in performing anticoagulation in this select pop-
ulation, results in a considerable dilemma about optimal
prophylaxis and treatment.11,15 The purpose of this retro-
spective analysis was to examine the incidence of DVT, risk
factors, and treatment patterns at a single high-volume,
tertiary-care, inpatient pediatric hospital.
Our data reveal that the incidence of pediatric DVTs
increased during a 14-year period from 1992 to 2005. The
incidence of childhood thromboembolic events in our pop-
ulation was higher (9.7 per 10,000 admissions) than other
reports (4.9-8.0 per 10,000 admissions).3,7,16 This obser-
vation may be because Riley Hospital is Indiana’s only
comprehensive pediatric medical center and one of the
largest pediatric intensive care hospitals in the country.
Rapid technologic improvements that have aided in the
care of acutely ill childrenmay have had a positive impact on
this reported trend.17 Patient demographics from our study
approximate pediatric VTE statistics reported from other
comparable centers.1-8 Collectively, these data corroborate
national and international trends that have identified DVT
as a growing concern among hospitalized children.1-7,16
Those children presenting with a DVT may well reflect
an older population of patients with DVT, as demonstrated
by a predominance of prior DVT and thrombophilic con-
ditions. The femoropopliteal venous system is most com-
monly involved.11,14,18 These children are generally older
and healthier at the time of admission than their counter-
parts with DVT acquired while in the hospital. These
children are admitted and with treatment are rapidly dis-
charged.
Those children with a DVT acquired while hospitalized
Table VI. Outcomes between groups I and II
Outcome Group I, No (%) Group II, No (%) P
Pulmonary embolism 1 (2.4) 4 (7.0) .30
Recurrent DVT 8 (19.0) 9 (15.8) .67
Major bleeding 0 0 1.0
Death 2 (4.8) 1 (1.8) .39
DVT, Deep venous thrombosis.demonstrated a bimodal distribution of age range, withsparing of group aged 6 to 10 years. This has been recog-
nized by other investigators.11,14 These patients are quite
ill and are often in an ICU setting for days. The major risk
factor associated with DVT in our patients was the presence
of a central catheter. About 50% of the catheters in our
series were in the upper extremity, which helps to explain
the shift in DVT location to the upper extremity and neck.
In some series,50% of the reported VTEs were located in
the upper extremities due to the presence of a central
catheter.11,19 Our series was not so heavily shifted to the
upper extremity because the remaining 50% of central
catheters were located in the femoral vein, with thrombosis
occurring there. In toto, these patients are at high risk for
DVT.
The patients who develop an inpatient DVT have seri-
ous health issues. Cancer and sepsis are well accepted risk
factors for venous thromboses; a growing body of literature
suggests that acute infection is a trigger for VTEs.20-22
Recently, Smeeth et al23 found the risk of DVT increased
after acute respiratory and urinary tract infections in adults.
Altered coagulation states and venous thromboses have
been reported in children with meningococcal infections,
osteomyelitis, and Mycoplasma pneumoniae.24-26 Our data
support the observation that children with fever and an
infectious source are at risk of developing a DVT.
It has been reported that catheter-related thrombosis
(CRT) is themost frequent cause of pediatric DVT, and the
incidence of CRT is increased in children with cancer
compared with adults.27,28 Vessel size in relation to cathe-
ter size has been implicated along with changes in the
fibrinolytic system. Our data support this observation. Al-
though we did not focus on patients with asymptomatic
CRT, asymptomatic CRT appears to be even more com-
mon than symptomatic CRT.29 Central venous catheters
are a prevalent risk factor for DVT in hospitalized children,
but whether all inpatients with a central line should un-
dergo prophylaxis is a lingering question and one not
supported by current guidelines.11
Physical or pharmacologic DVT prophylaxis is infre-
quently used in pediatric patients due to a perceived low
incidence of VTEs occurring in children. In our series, only
9.2% of patients were provided this care. Even in these
patients, the treatment must not have been sufficient be-
cause the patients eventually experienced a DVT. Unfortu-
nately, these findings are not unique to the pediatric pop-
ulation, because large registries indicate a high proportion
of inpatient adults with significant DVT risk factors are
likewise not properly considered for venous thrombosis
prophylaxis.30,31 Few studies have addressed the optimal
age for considering DVT prophylaxis. Azu et al32 con-
cluded it was safe to withhold VTE prophylaxis in pediatric
trauma patients aged 13 years secondary to a paucity of
clinically significant VTEs.32 Lack of data on DVT preven-
tion makes it difficult to determine which at-risk children
actually would benefit from thromboprophylaxis.
The alternative to prophylaxis would be a reliable clin-
ical indicator that could predict the true absence or pres-
ence of DVT and thereby allow appropriate treatment. In
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able as a stand-alone tool to rule in or out DVT on clinical
grounds alone. This is not surprising for two reasons.
Children are not adults and likely would require a system
validated specifically for children. Furthermore, the Wells
criteria are not an acceptable stand-alone method even in
adults, which explains the interest in the D-dimer test to
improve accuracy.33 Clearly, if we are going to protect
these children at risk for DVT, guidelines for pediatric DVT
prophylaxis must be developed from level 1 data.
Our study suggests that children at highest risk for
DVT are those who are admitted with severe respiratory,
oncologic, and infectious diseases that require central cath-
eter access for care and a prolonged ICU and hospital stay.
These children should be considered candidates for DVT
prophylaxis because they are the patients most likely to be
affected. But this recommendation is based on the limited
nature of this study and clearly lacks supporting level 1
evidence.
What is ultimately needed is a concerted effort to define
the patients at risk. All children admitted to the hospital
should be assessed for DVT risk coupled with a method of
reassessment if the hospital stay extends beyond a few days.
Several risk score tools are available, but none have been
validated for children.12,34 If DVT is suspected, appropri-
ate diagnostic studies should be obtained. By using proac-
tive protocols that identify children at risk coupled with an
established process of re-evaluation, at the worst, early
detection and treatment will be facilitated; at best, factors
unique to children that define those at high risk will be
recognized (a pediatric-specific risk stratification system)
and lead to guidelines for prophylaxis.
Treatment management recommendations for pediat-
ric DVTwere initially proposed by the AACP in 1995, with
revisions approximately every 3 years (1998, 2001, and
2004).11,14,35,36 The change most notable in the 2001
ACCP consensus statement was the introduction of
LMWH to the pediatric specialist both as a short-term
treatment and for long-term treatment in some cases.14
Long-term treatment and for at least 3 months has been a
constant recommendation. Our data demonstrate a deeper
incorporation of LMWH into the care of children with
DVT during both phases of treatment. A greater percent-
age of children were discharged with anticoagulation ther-
apy in group II and according to guideline recommenda-
tions. Unfortunately, our long-term duration of treatment
was shortened for unexplained reasons.
CONCLUSION
Our data suggest that the incidence of DVT in hospi-
talized children is increasing and therefore demands more
clinical attention. Those presenting with DVT are typical of
those afflicted with a spontaneous DVT: prior DVT,
thrombophilia, and lower extremity disease. Hospitalized
patients are quite ill, requiring central venous access often
through the femoral vein. The presence of the central
catheter predisposes to a local DVT. A clinical probability
scoring system alone cannot stratify patients sufficiently toforego prophylaxis in hopes of a rapid clinical diagnosis and
treatment. Therefore, pediatric-specific level 1 trials aimed
at determining guidelines for DVT prophylaxis are urgently
required. The results of this study indicate that the children
most at risk to develop DVT while in the hospital are those
admitted with severe respiratory, oncologic, and infectious
diseases who require a prolonged ICU and hospital stay and
who require central venous access during their manage-
ment. These children should be considered candidates for
DVT prophylaxis.
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